Pilar Ayuda-Duran
Overview
Explore the profile of Pilar Ayuda-Duran including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
75
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Fuentes-Martin R, Ayuda-Duran P, Hanes R, Gallego-Yerga L, Wolterinck L, Enserink J, et al.
Eur J Med Chem
. 2024 Jul;
275:116617.
PMID: 38959729
Agents that cause apoptotic cell death by interfering with tubulin dynamics, such as vinblastine and paclitaxel, are an important class of chemotherapeutics. Unfortunately, these compounds are substrates for multidrug resistance...
2.
Andersen A, Brodersen A, Ayuda-Duran P, Piechaczyk L, Tadele D, Baken L, et al.
Cell Rep Methods
. 2023 Dec;
3(12):100654.
PMID: 38065095
Current treatment selection for acute myeloid leukemia (AML) patients depends on risk stratification based on cytogenetic and genomic markers. However, the forecasting accuracy of treatment response remains modest, with most...
3.
Ayuda-Duran P, Hermansen J, Giliberto M, Yin Y, Hanes R, Gordon S, et al.
Cell Death Discov
. 2023 Dec;
9(1):435.
PMID: 38040674
The principle of drug sensitivity testing is to expose cancer cells to a library of different drugs and measure its effects on cell viability. Recent technological advances, continuous approval of...
4.
Chen Y, He L, Ianevski A, Ayuda-Duran P, Potdar S, Saarela J, et al.
Nat Protoc
. 2023 Nov;
19(1):60-82.
PMID: 37996540
Most patients with advanced malignancies are treated with severely toxic, first-line chemotherapies. Personalized treatment strategies have led to improved patient outcomes and could replace one-size-fits-all therapies, yet they need to...
5.
Tislevoll B, Hellesoy M, Fagerholt O, Gullaksen S, Srivastava A, Birkeland E, et al.
Nat Commun
. 2023 Mar;
14(1):1767.
PMID: 36997540
No abstract available.
6.
Tislevoll B, Hellesoy M, Fagerholt O, Gullaksen S, Srivastava A, Birkeland E, et al.
Nat Commun
. 2023 Jan;
14(1):115.
PMID: 36611026
Aberrant pro-survival signaling is a hallmark of cancer cells, but the response to chemotherapy is poorly understood. In this study, we investigate the initial signaling response to standard induction chemotherapy...
7.
Hanes R, Ayuda-Duran P, Ronneberg L, Nakken S, Hovig E, Zucknick M, et al.
Bioinformatics
. 2022 Dec;
39(1).
PMID: 36573326
Motivation: There is a rapidly growing interest in high-throughput drug combination screening to identify synergizing drug interactions for treatment of various maladies, such as cancer and infectious disease. This creates...
8.
Melvold K, Giliberto M, Karlsen L, Ayuda-Duran P, Hanes R, Holien T, et al.
Mol Oncol
. 2021 Dec;
16(5):1153-1170.
PMID: 34861096
Most patients with chronic lymphocytic leukemia (CLL) initially respond to targeted therapies, but eventually relapse and develop resistance. Novel treatment strategies are therefore needed to improve patient outcomes. Here, we...
9.
Grad I, Hanes R, Ayuda-Duran P, Kuijjer M, Enserink J, Meza-Zepeda L, et al.
PLoS One
. 2021 Mar;
16(3):e0248140.
PMID: 33690666
Sarcomas are a heterogeneous group of mesenchymal orphan cancers and new treatment alternatives beyond traditional chemotherapeutic regimes are much needed. So far, tumor mutation analysis has not led to significant...
10.
Tadele D, Robertson J, Crispin R, Herrera M, Chlubnova M, Piechaczyk L, et al.
J Biol Chem
. 2020 Dec;
296:100179.
PMID: 33303632
Breakpoint Cluster Region-Abelson kinase (BCR-Abl) is a driver oncogene that causes chronic myeloid leukemia and a subset of acute lymphoid leukemias. Although tyrosine kinase inhibitors provide an effective treatment for...